论文检索
期刊
全部知识仓储预印本开放期刊机构
高级检索

拉莫三嗪片在中国健康受试者中的生物等效性的研究OA北大核心CSTPCD

Bioequivalence of lamotrigine tablets in Chinese healthy subjects

中文摘要英文摘要

目的 研究拉莫三嗪片在中国健康受试者中的药代动力学特征,并评价国产拉莫三嗪片受试制剂(T)和原研参比制剂(R)在空腹和餐后条件下的生物等效性及安全性.方法 空腹和餐后试验分别入组24例中国健康受试者,空腹试验男性18例,女性6例,餐后试验男性17例,女性7例,采用单中心、随机、开放、单剂量、两制剂两周期两序列交叉的试验设计,受试者单次口服拉莫三嗪片受试制剂或参比制剂50 mg后采集72 h血样,用液质联用法(LC-MS/MS)测定血浆中拉莫三嗪浓度,用WinNonLin 8.1计算主要药代动力学参数并评价2种拉莫三嗪片的生物等效性.结果 空腹单次给药拉莫三嗪片受试制剂和参比制剂的 Cmax分别为(910.93±248.02)和(855.87±214.36)ng·mL-1,tmax分别为0.50(0.25,4.00)和 1.00(0.25,3.50)h,t1/2分别为(36.1±9.2)和(36.0±8.2)h,AUC0-72h分别为(27 402.40±4 752.00)和(26 933.90±4 085.80)h·ng·mL-1.餐后单次给药拉莫三嗪片受试制剂与参比制剂的Cmax分别为(701.62±120.67)和(718.95±94.81)ng·mL-1,tmax分别为 4.00(1.00,5.00)和 4.00(0.50,5.00)h,t1/2 分别为(44.2±12.4)和(44.0±12.0)h,AUC0-72h 分别为(30 253.20±7 018.00)和(30 324.60±6 147.70)h·ng·mL-1.空腹试验和餐后试验受试制剂/参比制剂的拉莫三嗪主要药代动力学参数经对数转换后几何均值比(90%CI)均落在80.00%~125.00%,服用2种拉莫三嗪片均未发生严重不良反应,安全性良好.结论 2种拉莫三嗪片在空腹和餐后状态下在中国男性和女性健康受试者体内生物等效、安全.

Objective To study the pharmacokinetic characteristics of lamotrigine tablets in Chinese healthy subjects under fasting and fed conditions,and to evaluate the bioequivalence and safety profiles between the domestic test preparation and the original reference preparation.Methods Twenty-four Chinese healthy male and female subjects were enrolled under fasting and fed conditions,18 male and 6 female subjects under fasting conditions,17 male and 7 female subjects under fed conditions.A random,open,single-dose,two preparations,two sequences and double-crossover design was used.Plasma samples were collected over a 72-hour period after give the test or reference preparations 50 mg under fasting and fed conditions.The concentration of lamotrigine in plasma was detected by liquid chromatography-tandem mass spectrometry,and the main pharmacokinetic parameters were calculated to evaluate the bioequivalence by WinNonLin 8.1 program.Results The main pharmacokinetic parameters of single-dose the tested and reference preparations were as follows:The fasting condition Cmax were(910.93±248.02)and(855.87±214.36)ng·mL-1;tmax were 0.50(0.25,4.00)and 1.00(0.25,3.50)h;t1/2 were(36.1±9.2)and(36.0±8.2)h;AUC0_72h were(27 402.40±4 752.00)and(26 933.90±4 085.80)h·ng·mL-1.The fed condition Cmax were(701.62±120.67)and(718.95±94.81)ng·mL-1;tmax were 4.00(1.00,5.00)and 4.00(0.50,5.00)h;t1/2 were(44.2±12.4)and(44.0±12.0)h;AUC0-72h were(30 253.20±7 018.00)and(30 324.60±6 147.70)h·ng·mL-1.The 90%confidence intervals of the geometric mean ratios of Cmax and AUC0-72 hfor the test preparation and reference preparation were all between 80.00%and 125.00%under fasting and fed conditions.Conclusion Two kinds of lamotrigine tablets are bioequivalent,and have similar safety in Chinese healthy male and female subjects under fasting and fed conditions.

姜金生;欧阳冬生;陈红英;陈俊;陈尧;陈开义;张雪花;胡杰;刘鑫;黄馨仪

中南大学湘雅医院临床药理研究所,湖南长沙 410001||三金集团湖南三金制药有限责任公司,湖南常德 415000中南大学湘雅医院临床药理研究所,湖南长沙 410001||复杂基质样本生物分析湖南省重点实验室,湖南长沙 410000中南大学湘雅医院临床药理研究所,湖南长沙 410001三金集团湖南三金制药有限责任公司,湖南常德 415000湖南省脑科医院精神科,湖南长沙 410007

药学

拉莫三嗪片;药代动力学;生物等效性;液相色谱-串联质谱

lamotrigine;pharmacokinetics;bioequivalence;liquid chromatography-tandem mass spectrometry

《中国临床药理学杂志》 2024 (006)

894-898 / 5

国家自然科学基金资助项目(82073942);湖南省自然科学基金资助项目(2022JJ80097、2022JJ80113)

10.13699/j.cnki.1001-6821.2024.06.023

评论

下载量:0
点击量:0